Free Trading + Demat Account

IPO Discussion Page

Please Note: All views and opinions expressed in reader comments are solely those of the individual submitting the comment, and not those of the Chittorgarh.com or its staff.

avatar
4234. jamesandy  Dec 11, 2016 4:22:15 PM IST Reply

Majestic Research Services & Solutions Ltd FPO

(WWW.Carder007.Live) Buy Dumps with pin track 1 and 2 cvv fullz verified seller

I am a verified online dumps cvv fulz seller. We sell fresh dumps, skimmed dumpsSell CVV DUMPS TRACK 1 TRACK 2 DUMPS WITH PIN good T1 and T2,have Good Base and vaild rate 95% bulk dumps with Pin and code 101,110,201,210,220 and more Country.


You will receive MTCN and other transaction codes in few minutes after payment confirmed because I will do transfer ONLINE.When I transfer for Western Union I need the following details from you.
I suggest you use drop or fake info and ID''s for verification when picking up money.

First Name:_____________________
Last Name:______________________
Your country:___________________
Your City:______________________
Payments by Western Union can now have option to user Secret Security Question where you do not need Passport/ID/etc. just to have secret answer. If you want this then just tell me in message before I transfer.
You just have to present your MTCN ( Money Transfer Control Number) and provide both the question and answe

Western Union RATES:

$1500WU for $250 BTC or PM Only
$2000 WU for $300 BTC or PM Only
$3000 WU for $400 BTC or PM Only
$4500 WU for $500 BTC or PM Only
$6000 WU for $600 BTC or PM Only
$7500 WU for $700 BTC or PM Only

Bank Transfer RATES:

$2000 Bank Transfer for $300 BTC or PM Only
$3000 Bank Transfer for $400 BTC or PM Only
$4000 Bank Transfer for $600 BTC or PM Only
$5000 Bank Transfer for $750 BTC or PM Only
$6000 Bank Transfer for $900 BTC or PM Only


PAYPAL TRANSFER

Now offering direct PayPal funds deposited straight into your account. This will work for any PayPal account worldwide.
PayPal deposits is done through external payment processors. These funds are NOT from hacked accounts.
All we need is your PayPal email, please leave it in Notes when ordering.

Paypal Transfer Rates:

$2000 Pypal Transfer for $300 BTC or PM Only
$3000 Pypal Transfer for $400 BTC or PM Only
$4000 Pypal Transfer for $600 BTC or PM Only
$5000 Pypal Transfer for $750 BTC or PM Only
$6000 Pypal Transfer for $900 BTC or PM Only

Contact :
-ICQ: 701666644
-Skype:ivcgroup1
-email:askltd@usa.com
-site: Carder007 dot live

avatar
4233. Jaikishan  Dec 11, 2016 4:09:02 PM IST Reply

Laurus Labs Ltd IPO

Any news about primium
avatar
4232. Niyaz varaiya  Dec 11, 2016 3:17:04 PM IST Reply

Sheela Foam Ltd IPO

I have short 20 shares of sheela at 1032
How much los will i get?
avatar
4232.1. ANIL VERMA  Dec 11, 2016 5:15:30 PM IST

Sheela Foam Ltd IPO

It will be bought in auction on Tuesday by exchane. You may roughly lose Rs 800-900
avatar
4232.2. ANIL VERMA  Dec 11, 2016 5:15:31 PM IST

Sheela Foam Ltd IPO

It will be bought in auction on Tuesday by exchane. You may roughly lose Rs 800-900
avatar
4231. IPO aspirant.  Dec 11, 2016 2:25:08 PM IST Reply

Laurus Labs Ltd IPO

Eagle eyeji, i applied in laurus on last day, i.e. Friday, i received confirmation frm nse, but i see that bank has not blocked fund, banks are closed for 3 days, what should i understand d status of appli.?
avatar
4231.1. jamesandy  Dec 11, 2016 4:23:10 PM IST

Laurus Labs Ltd IPO

(WWW.Carder007.Live) Buy Dumps with pin track 1 and 2 cvv fullz verified seller
avatar
4231.2. IPO aspirant.  Dec 11, 2016 4:34:14 PM IST
avatar
4231.3. Kuttu  Dec 11, 2016 4:54:26 PM IST

Laurus Labs Ltd IPO

If the ipo status is showing executed then it will be deducted on alloted day till that day amount will be blocked
avatar
4230. Jainvipul  Dec 11, 2016 2:05:08 PM IST Reply

Laurus Labs Ltd IPO

laurus lab
It derives a significant portion of its revenue from Generics – API business, which primarily comprises the sale of products in the therapeutic areas of ARVs, Hepatitis C and Oncology. For the financial years 2016, 2015 and 2014, its revenue from Generics – API business was Rs.16,516.84 million, Rs12,533.54 million and Rs10,907.17 million, or 92.2%, 92.1% and 93.3% of its total revenues, respectively. For the financial year 2016, Its revenue from the sale of APIs in the therapeutic areas of ARVs, Hepatitis C and Oncology accounted for Rs.12,619.09 million, Rs 1,970.98 million and Rs 1,413.38 million, or 70.4%, 11.0% and 7.9% of Its total revenues, respectively. Further, within its product portfolio in the ARV therapeutic area, it depends significantly on the sale of Efavirenz, Tenofovir Disoproxil Fumarate and Emtricitabine, the preferred first line treatment option for adults, pregnant and breast feeding women and adolescents
For the financial year 2016, it derived Rs 12,619.09 million, or 70.4% of its total revenues, from the sale of products in the ARV therapeutic area, which primarily comprised the sale of Efavirenz, Tenofovir Disoproxil Fumarate and Emtricitabine. These three products are currently used as one of the preferred first line treatment in the ARV therapeutic area, recommended by the WHO for its target markets.
It is dependent on a limited number of customers for a significant portion of its revenues. For the financial years 2016, 2015 and 2014, its top five customers contributed Rs 12,142.83 million, Rs 10,466.3 million and Rs 8,940.65 million, or 67.8%, 76.9% and 76.5% of total revenues, respectively
Over the last few years, it has expanded operations and services and experienced considerable growth. From the financial year 2012 to the financial year 2016, its total revenues, on a standalone basis, has increased from Rs 4,523.07 million to Rs 17,884.15 million. Although it has historically derived a significant percent of its revenue from Generics – API business, it is investing significant time and resources in growing its Generics – FDF, Synthesis and Ingredients businesses. It constantly seeks to develop its R&D capabilities to distinguish itself from the competitors to enable it to introduce new products.
It is in the process of setting up two additional manufacturing facilities, one for potent APIs (expected to commence operations by December 31, 2016) and the other for APIs, intermediates and ingredients (expected to commence construction during the financial year 2017). Post planned expansion, its aggregate reactor volume will increase to 2,095.6 KL during the financial year 2017.
To accomplish this, it commits substantial effort, funds and other resources towards R&D activities and it has set-up a dedicated R&D center in Hyderabad and Greater Boston and is currently in the process of setting up an R&D center in Visakhapatnam.
The Company spent Rs 906.52 million, Rs 586.49 million and Rs 424.40 million towards R&D activities during the financial years 2016, 2015 and 2014, or 5.1%, 4.3% and 3.6% of its total revenues in such years, respectively
As of June 30, 2016, the Company owned 32 patents and had 150 pending patent applications, in several countries.
Its net asset value per Equity Share, post the issue of bonus shares, was Rs 137.53 as on March 31, 2016, while it was Rs 135.06 as at March 31, 2016, as per its Restated Consolidated Financial Statements.
India is one among the top five pharmaceutical emerging markets globally and is a front runner in a wide range of specialties involving manufacturing and development of complex drugs. India has about 40% of all Abbreviated New Drug Application (ANDA) approvals from US FDA. The Indian API manufacturing industry is the third largest in the world, producing over 400 APIs. Globally Indian companies hold more than 90% of APIs approvals for ARVs, Anti-Tuberculosis and Anti-malarials.
The company is a leading research and development (“R&D”) driven pharmaceutical company in India, with a leadership position in generic active pharmaceutical ingredients (“APIs”) for revenue, were its customers.
It has set-up its first dedicated R&D center in Hyderabad, Telangana in 2006 & initially focused on research in the Oncology and ARV API areas and after making progress in R&D it commissioned first API manufacturing facility in 2007. The kilo lab at R&D center at Hyderabad has received approvals from the United States Food and Drug Administration (“US FDA”), Pharmaceuticals and Medical Devices Agency (“PMDA”) of Japan and the Korea Food and Drug Administration (“KFDA”). It has also set up a R&D center in Greater Boston, United States in 2015. As of June 30, 2016, it employed 587 scientists at its R&D center in Hyderabad and 12 scientists at its R&D centre in Greater Boston, which constituted 25.0% of total employee strength. The Company spent Rs 906.52 million, Rs 586.49 million and Rs 424.40 million towards the R&D activities during the financial years 2016, 2015 and 2014, or 5.1%, 4.3% and 3.6% of its total revenues in such periods, respectively.
It is currently in the process of expanding R&D center in Hyderabad and setting up another R&D center in Visakhapatnam, Andhra Pradesh. It believes that systematic approach to the commercialization of 30 out of the 37 filed DMFs, as of June 30, 2016. As of June 30, 2016, the Company owned 32 patents and had 150 pending patent applications, in
several countries.
So, one issue is undoubted clear that this company has solid potential to grow.
Now the question is whether the price band is reasonable or is on higher side.Many of the experts believe the price band is on higher side. Let us discuss it out:
Consolidated EPS Year ended on March 31, 2016 Rs. 20.86( as per RHP) .( EPS calculation is a tricky affair due to issuance of bonus shares) The company during last 4 financial years has achieved CAGR of 60%. so lets assume that it may earn atleast Rs. 32 for the current year 2016-17. So upper price band is at PE multiple of 13.37 on estimated EPS for 2016-17. Will you consider it on higher side ?
Book value As on March 31, 2016 Unconsolidated Rs. 137.53 & Consolidated Rs. 135.06( after adjustment of Bonus shares) So upper Price Band/BV = 3.17/1 .
Compare it with Divis CMP Rs. 1133/BV Rs. 161= 7.03/1 & Aurobindo Pharma CMP Rs. 730/BV Rs. 121= 6.03/1. So from book value angle also , you will agree that price band is reasonable.Since EPS & PE are tricky affair and many analysts consider PE multiple for this IPO on very higher side, I will prefer to give more weight to CMP/BV aspect while valuing this IPO.
The Only risk, I believe, at present is current volatility in the Stock-market and if you wish to take that risk, I believe that one should not forgo this IPO & may Apply
avatar
4229. Mukesh kathiriya  Dec 11, 2016 2:03:29 PM IST Reply

Laurus Labs Ltd IPO

Lauras lab listing prise ??
avatar
4228. Virat Kohli  Dec 11, 2016 1:35:49 PM IST Reply

Laurus Labs Ltd IPO

Page Industries : a proven wealth builder for Septa ji.
Similarly , In womens segment "Womens Next" is also emerging at faster rate.
septa ji, pls enlighten us.
everyone can share any running insight news or rumour .
avatar
4228.1. Aman  Dec 11, 2016 3:09:35 PM IST

Laurus Labs Ltd IPO

womens next : EPS is positive but operating cash flow is negative.

it means its inventory/ receivables are piling up and they are reporting some cooked numbers.
avatar
4227. satyanarayana.c  Dec 11, 2016 1:34:55 PM IST Reply

Laurus Labs Ltd IPO

Process of allotment ....???????
avatar
4226. satyanarayana.c  Dec 11, 2016 1:34:14 PM IST Reply

Laurus Labs Ltd IPO

Hi...any body knows how to allot the shares in employees Quota....
avatar
4225. Siddharaj  Dec 11, 2016 12:22:47 PM IST Reply
avatar
4224. Siddharaj  Dec 11, 2016 12:21:59 PM IST Reply

Laurus Labs Ltd IPO

Hi experts, I have applied for 35 shares will I be allowed??
avatar
4223. gravitaparol  Dec 11, 2016 11:11:05 AM IST Reply

Laurus Labs Ltd IPO

if you have 1 lac rupees.
bifurcate this type
total 100%
35%short term
45%medium term
20%long term

short term for btst to one month(include ipo)
medium term for 6-12 months.
long term for above 12 months.

short term (wait and watch)
medium term(gnfc,sparc)
long term(bombaydying,gitanjali)

for long term choose script which slow but constatnt growth.
for medium term choose script which high growth.
for short term depend on mkt scenario.
avatar
4223.1. MahiMahi  Dec 11, 2016 11:23:20 AM IST
avatar
4223.2. MahiMahi  Dec 11, 2016 12:43:20 PM IST
avatar
4222. Gingal  Dec 11, 2016 10:48:21 AM IST Reply

Sheela Foam Ltd IPO

Subscribe ipo in full lot message given by Eagleeye men at perfect time. I got 4 lot. Thanx Eagle Eye .
avatar
4222.1. Gingal  Dec 11, 2016 11:56:53 AM IST

Sheela Foam Ltd IPO

Sorry its Eagleeye mem not man
avatar
4221. MahiMahi  Dec 11, 2016 10:11:51 AM IST Reply

Laurus Labs Ltd IPO

Which Five stock should I have consider for next 3 years? I have almost 1lakh to invest in. So instead of 1 stock to invest in considering to invest in 5 stocks.
avatar
4221.1. MahiMahi  Dec 11, 2016 10:33:18 AM IST

Laurus Labs Ltd IPO

Sbi, gujalkalies, jkinfra, maruti Suzuki, mngl and hcc
avatar
4221.2. gravitaparol  Dec 11, 2016 10:51:13 AM IST

Laurus Labs Ltd IPO

these two stocks should add in your portfolio
gnfc,sparc
avatar
4220. gamble  Dec 11, 2016 9:16:11 AM IST Reply

Laurus Labs Ltd IPO

Aurobindo pharma incorporate in 1986
Divis lab in 1990

Last 5 yr

Aurobindo 80 to 800
Divis lab 400 to 1300


Now we hv laurus lab incorporate in 2005

15 yrs younger than these 2.

So high growth in coming days compare to these 2 biggies is very much promising.
And hence price growth...!!!



Laurus lab @428 available at

2016 32x PE
2017 23x PE
2018 17x pE
2019 13x pE
2020 10x PE

Only given 35% growth..!!
avatar
4220.1. Mann Ki Baat  Dec 11, 2016 3:46:04 PM IST

Laurus Labs Ltd IPO

good analysis of forward PE
avatar
4219. Ravidesai  Dec 10, 2016 11:56:55 PM IST Reply

Sheela Foam Ltd IPO

I have short delivery of 200 shares at price of 889. What amount have to pay?
avatar
4219.1. Ashish Khater  Dec 11, 2016 2:17:48 AM IST

Sheela Foam Ltd IPO

Seeing the momentum in the stock.....50000 you will have to pay... assuming momentum will take it 100 rs more up till your trade is settled in auction
avatar
4218. NAVEEN KUMAR  Dec 10, 2016 11:41:59 PM IST Reply

Laurus Labs Ltd IPO

Can anyone check the PE of AEL?
its just 63

and

Laurus is 34 looking big

its your decision tight your seat belts and wait for atleast 10days after listing
avatar
4217. NAVEEN KUMAR  Dec 10, 2016 11:35:13 PM IST Reply

Laurus Labs Ltd IPO

Laurus Lab be another Advanced Enzymes

its mainly Research Firm like MNC Pharma and no comparison with traditional indian pharma companies that run on manufacturing only

see the returns by MNC Pharma
avatar
4216. VINOD JAIN NICKY  Dec 10, 2016 10:30:29 PM IST Reply

Laurus Labs Ltd IPO

LAURUS MAY BE A CHHUPA RUSTOM AFTER ITS LISTING. SOMETHING LIKE SHEELA KI JAWANIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII
avatar
4215. gravitaparol  Dec 10, 2016 10:23:04 PM IST Reply

Laurus Labs Ltd IPO

if fed will declare rate unchange ,mkt will zoom

but rate hike ,doller index will go down

two things use as money in whole world
1.US doller
2.gold
special_offers
By Popular Stock Brokers
ProStocks, The Flat Rate Discount Stock Broker
ProStocks
Flat Fee Broker

Rs 899 Unlimited Equity
Rs 499 Unlimited Curr
or Rs 15 per Trade

Lowest Transaction Charge
Lowest Call & Trade Fee
Lowest Stamp Duty

FREE Trading + Demat Acct

Flat Rs 20 Per Trade
Free Equity Delivery Trades

Rs 100 off on account opening* + 100% brokerage refund if in 60 days you have made net profits

Enquire Now
(* on online account opening)

Intraday @ 0.02%
Delivery @ 0.15%

Rs 0 account opening fee
(Rs 400 waived)

Request Demo

RKSV Discount Broker  RKSV

Ditch & Switch

Switch to RKSV and earn brokerage credit of Rs 2000

Get RKSV Trading Account

Beginner, seasoned investor, active trader or HNI. Get customised solutions.

Rs 0 account opening fee on Online Trading + Demat Acct
(Rs 1150 waived)

Request Call Back



More About Brokers

Special Offers Broker Reports

Message Board

Stock Message Board


Search Chittorgarh.com:

Translate Chittorgarh.com: